Clinical Trials Logo

Anti-PD-1 Antibody clinical trials

View clinical trials related to Anti-PD-1 Antibody.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04188860 Completed - Immunotherapy Clinical Trials

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or treatment. The marketing of anti-PD-1 antibody has provided an opportunity of curative management. This single arm, open, phase II trial would recruit 34 eligible patients. A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for first 9 patients. If at least total 2 patients achieved complete or partial remission, or at least total 6 patients achieved complete or partial remission or stable disease, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.